Phase Ib/III Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Patients With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
The purpose of this phase Ib/III study is to evaluate the safety and feasibility of RYZ101 in comparison to standard of care therapy (Everolimus, Sunitinib, Octreotide, Lanreotide) in patients with advanced staged, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment.
Study ID: RYZ101-301
Trial Phase: Phase I/II
Trial Sponsor: RayzeBio, Inc.
Therapies Used in This Trial: Everolimus, Octreotide Acetate, Lanreotide, Sunitinib, RYZ101